NCT04043195View on ClinicalTrials.gov

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 14, 2019

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Advanced NSCLC
Interventions
DRUG

Nivolumab

240 mg every 2 weeks. Nivolumab will continue for up to 2 years.

DRUG

Oxaliplatin

65 mg/m2 every 2 weeks. Oxaliplatin will continue for up to 12 cycles.

DRUG

Ipilimumab

1 mg/kg every 6 weeks. Ipilimumab will continue for up to 4 cycles

Trial Locations (1)

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
lead

Hatim Husain

OTHER